Hims & Hers Health, Inc. Class A Common Stock (HIMS)
17.46
-5.56 (-24.17%)
NYSE · Last Trade: Feb 9th, 12:05 PM EST
Detailed Quote
Previous Close
23.02
Open
17.83
Bid
17.45
Ask
17.46
Day's Range
16.35 - 17.97
52 Week Range
21.12 - 72.98
Volume
78,259,641
Market Cap
3.35B
PE Ratio (TTM)
32.93
EPS (TTM)
0.5
Dividend & Yield
N/A (N/A)
1 Month Average Volume
22,641,764
Chart
About Hims & Hers Health, Inc. Class A Common Stock (HIMS)
Hims & Hers Health Inc is a telehealth company that focuses on providing accessible and affordable healthcare solutions for a variety of needs, particularly focusing on personal wellness and self-care. The company offers a range of products and services, including prescription medications for conditions such as hair loss, erectile dysfunction, and skincare, as well as wellness supplements and telemedicine consultations. By leveraging technology, Hims & Hers aims to simplify the healthcare experience, making it more convenient for consumers to receive treatment and advice from licensed professionals without the barriers typically associated with traditional healthcare delivery. Read More
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 23.6% in the morning session after the company stopped offering its copycat version of Novo Nordisk's popular weight-loss drug, Wegovy, following intense regulatory pressure and legal action.
The multi-billion dollar weight-loss drug market experienced a seismic shift this morning as the era of easy-access compounded alternatives faced its most significant legal and regulatory challenge to date. On February 9, 2026, pharmaceutical giant Novo Nordisk (NYSE: NVO) filed a landmark patent infringement lawsuit against Hims & Hers Health, Inc.
The meteoric rise of telehealth giant Hims & Hers Health (NYSE: HIMS) faced its most severe reckoning this week, as the company’s stock plummeted to a one-year low following a dramatic withdrawal of its highly anticipated oral weight-loss treatment. What was intended to be a disruptive move against the pharmaceutical
On February 9, 2026, the telehealth landscape faces a reckoning. Hims & Hers Health (NYSE: HIMS), a company that once seemed invincible during the weight-loss drug gold rush of 2025, is currently grappling with a sharp 20% decline in its stock price over the past week. The catalyst for this sudden valuation haircut is a [...]
Retail bulls pointed to similar price levels during high short interest in late 2024 and said ending compounded sales removes the risk of a costly legal fight.
As the Seattle Seahawks and New England Patriots prepare to take the field for Super Bowl LX at Levi’s Stadium, the real action is happening on digital ledger boards and order books. In a historic first for the industry, the 2026 Super Bowl has become the most heavily traded sporting event in the history of [...]
The U.S. Food and Drugs Administration Commissioner Martin A Makary announced the agency’s intent to restrict the ingredients used by Hims as alternatives to FDA-approved drugs.
The long-standing duopoly of the weight-loss drug market faced its most significant challenge yet this week as Hims & Hers Health, Inc. (NYSE: HIMS) announced a breakthrough $49 compounded oral semaglutide pill. The move, aimed directly at the market share of pharmaceutical titans Eli Lilly and Company (NYSE: LLY) and Novo
In a dramatic week for the pharmaceutical sector, a stark rift has opened between the two undisputed titans of the weight-loss drug market. On February 4, 2026, Eli Lilly (NYSE:LLY) reported a staggering 45% surge in full-year 2025 revenue, propelled by the insatiable global demand for its blockbuster treatments,
